Better protection for patentees: preliminary injunctions in the EU for pharmaceutical patent matters

By von Falck Andreas   Gundt Miriam  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 3, 2013-05 ,pp. : 291-293

Future Science

Access to resources Recommend Favorite

Pharmaceutical patent litigation in Europe

By Cook T.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 2, 1999-02 ,pp. : 181-187

Informa Healthcare

Access to resources Recommend Favorite

The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry

By Burton Carlyn A   Margonis Lisa E  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 177-180

Future Science

Access to resources Recommend Favorite

Different rules, different results: patent litigation after In re Baxter

By Vogel Bryan J   Roberg-Perez Sharon E  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 3, 2013-05 ,pp. : 295-297

Future Science

Access to resources Recommend Favorite

Medicaid spent an extra $US329 million in 2009 by buying 20 branded drugs instead of their generic equivalents

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 626, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite